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ABSTRACT
Hypoxic injury to cardiomyocytes is a stress that causes cardiac pathology through cardiac-
restricted gene expression. SRF (serum-response factor) and myocardin are important for
cardiomyocyte growth and differentiation in response to myocardial injuries. Previous studies
have indicated that AngII (angiotensin II) stimulates both myocardin expression and cardiomyocyte
hypertrophy. In the present study, we evaluated the expression of myocardin and AngII after
hypoxia in regulating gene transcription in neonatal cardiomyocytes. Cultured rat neonatal
cardiomyocytes were subjected to hypoxia, and the expression of myocardin and AngII were
evaluated. Different signal transduction pathway inhibitors were used to identify the pathway(s)
responsible for myocardin expression. An EMSA (electrophoretic mobility-shift assay) was used to
identify myocardin/SRF binding, and a luciferase assay was used to identify transcriptional activity
of myocardin/SRF in neonatal cardiomyocytes. Both myocardin and AngII expression increased
after hypoxia, with AngII appearing at an earlier time point than myocardin. Myocardin expression
was stimulated by AngII and ERK (extracellular-signal-regulated kinase) phosphorylation, but was
suppressed by an ARB (AngII type 1 receptor blocker), an ERK pathway inhibitor and myocardin
siRNA (small interfering RNA). AngII increased both myocardin expression and transcription in
neonatal cardiomyocytes. Binding of myocardin/SRF was identiﬁed using an EMSA, and a luciferase
assay indicated the transcription of myocardin/SRF in neonatal cardiomyocytes. Increased BNP
(B-type natriuretic peptide), MHC (myosin heavy chain) and [3H]proline incorporation into
cardiomyocytes was identiﬁed after hypoxia with the presence of myocardin in hypertrophic
cardiomyocytes. In conclusion, hypoxia in cardiomyocytes increased myocardin expression,
which is mediated by the induction of AngII and the ERK pathway, to cause cardiomyocyte
hypertrophy. Myocardial hypertrophy was identiﬁed as an increase in transcriptional activities,
elevated hypertrophic and cardiomyocyte phenotype markers, and morphological hypertrophic
changes in cardiomyocytes.
Key words: angiotensin II, cardiomyocyte hypertrophy, extracellular-signal-regulated kinase (ERK), myocardin, serum-response
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INTRODUCTION
The heart responds to different stress signals, including
biomechanical stress, tissue injury, oxidative stress or
neurohumoral activation, and this response may result
in hypertrophic growth as indicated by an increase in
cardiomyocyte size and protein content, cytoskeleton
re-organization and expression of fetal cardiac genes
[1–3]. Sustained cardiac hypertrophy may ﬁnally lead
to cardiomyopathy, heart failure, arrhythmia and even
sudden cardiac death, which contribute to a major
cause of morbidity and mortality [4,5]. Hypoxia elicits
a variety of functional responses in cardiomyocytes,
including cell proliferation, cell hypertrophy and cell
death. Cardiomyocytes respond to hypoxia to maintain
homoeostasis by expressing a number of genes, which
are induced by a variety of signalling cascades [1–4].
However, the detailed signalling mechanisms activated
in cardiomyocytes in response to hypoxia remain
unclear. Understanding the oxygen-sensitive pathways
in cardiomyocytes might help in the development of
therapies for hypoxia-induced cardiovascular diseases.
Myocardin, a recently discovered novel and potent
transcriptional cofactor, co-operates with SRF (serum-
response factor) and plays an important role in the
gene regulation of cardiac and smooth muscle cell
growth and differentiation [6–13]. Previous studies have
indicated that forced expression of myocardin induces
cardiomyocyte hypertrophy [14–17]. Other studies have
also indicated that pressure overload or biomechanical
stressmaystimulatehypertrophicsignals[i.e.ANF(atrial
natriuretic factor) and BNP (B-type natriuretic peptide)]
and result in cardiomyocyte hypertrophy through
increased transcriptional activities of myocardin/SRF in
cardiomyocytes [15]. Increased myocardin expression in
failing aging human and porcine myocardium compared
with healthy individuals has been identiﬁed [18].
Myocardin is also up-regulated in aging and end-stage
failing human hearts. Fibroblasts from post-myocardial
infarction scars acquiring properties of cardiomyocytes
after transduction with the recombinant myocardin gene
has been another promising ﬁnding [16]. According to
previous studies [19,20], myocardin transcription and
protein levels are increased by hypertrophic stimuli,
which may account for the increase in myocardin-
dependent gene expression, and myocardin activity is
stimulated by hypertrophic signalling, most probably
through post-translational modiﬁcation.
Hypoxic/ischaemic injury is another major stress to
the heart, which may lead to cardiomyocyte pathology
through fetal cardiac gene expression and speciﬁc signal
transduction pathways. Previous studies have indicated
that hypoxia in cardiomyocytes results in cardiomyocyte
hypertrophy and remodelling, which was blocked by
ARBs {AT1R [AngII (angiotensin II) type 1 receptor]
blockers}[21,22].EarlierstudiesalsoindicatedthatAngII
stimulated both myocardin expression and target gene
transcription in VSMCs (vascular smooth muscle cells)
to cause VSMC hypertrophy[23,24]. AngII has also been
identiﬁed as a stimulator of cardiomyocyte hypertrophy
in many studies [25,26]. However, the expression of
AngIIandmyocardinafterhypoxiaandtheirrelationship
in regulating gene transcription in cardiomyocytes in
response to hypoxia has not been well deﬁned.
Therefore we developed the hypothesis that hypoxia-
related myocardial injury may result in cardiomyocyte
hypertrophy by expressing certain cardiac-restricted
genes through speciﬁc signal transductional pathways.
Myocardin may play an important role in regulating
this expression. Hypertrophic markers (ANF and BNP)
and cardiomyocyte-restricted gene modulation may
also be identiﬁed in response to myocardin expression
through speciﬁc signal transduction pathways after
hypoxia. AngII, a potent stimulator of cardiomyocyte
hypertrophy, may be expressed in response to hypoxia
to enhance myocardin expression and cardiomyocyte
gene transcription as shown previously in VSMC models
[23,24]. However, the speciﬁc transduction pathway(s)
mediating these mechanisms remain to be identiﬁed after
hypoxic injury.
In the present study, we investigated the effect
of hypoxia on the expression of myocardin in
neonatal cardiomyocytes and the potential signalling
mechanisms mediating its expression. We demonstrate
that hypoxia in neonatal cardiomyocytes increased
the expression of myocardin and this appeared to
be mediated via AngII and the ERK pathway. In
addition, cardiomyocytes exposed to hypoxia had an
increase in the expression of BNP and MHC (myosin
heavy chain), increased [3H]proline incorporation in
cardiomyocytes, and increased transcriptional activities
inducing cardiomyocyte hypertrophy.
MATERIALS AND METHODS
Primary culture of left ventricular
cardiomyocytes
Cardiomyocyteswereobtainedfrom2–3-day-oldWistar
rats by trypsinization, as described previously [27,28].
Cultured myocytes thus obtained were >95% pure, as
revealed by observing their contractile characteristics
usingalightmicroscopeandstainingwithananti-desmin
antibody (Dako Cytomation). The culture medium
consisted of DMEM/F12 (Dulbecco’s modiﬁed Eagle’s
medium/Ham’s F12) supplemented with 20% (v/v)
knockout serum replacement, 1% (v/v) non-essential
amino acids, 2 mmol/l l-glutamine, 0.1% 2-mercapto-
ethanol and 0.1% of a commercially available peni-
cillin/streptomycin stock solution (100 units/ml
penicillin and 100 μg/ml streptomycin; Invitrogen).
Cells were then transferred to serum-free medium and
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maintained for another 2 days. The enriched myocytes
were then subjected to hypoxia.
The animals were handled according to the Guide
for the Care and Use of Laboratory Animals published
bytheUSNationalInstitutesofHealth(NIHPublication
No 85-23, revised 1996). The study was reviewed and
approved by the Institutional Animal Care and Use
Committee of Shin Kong Wu Ho-Su Memorial Hospital.
Induction of hypoxia
Hypoxic conditions were achieved by adding medium
pre-equilibrated with nitrogen gas to cells prior to
the incubation in a Plexiglas chamber purged with
water-saturated nitrogen gas using an oxygen controller
(PROOX model 110; BioSpherix). The Po2 (partial
pressureofoxygen)oftheculturemediumunderhypoxia
was monitored using an ISO2 dissolved oxygen meter
(World Precision Instruments). Measurements indicated
that a steady state in the culture medium was maintained
during the experiments. Hypoxic culture medium
(BioSpherix C-chamber) was used with mixed air in
and out controlled by a BioSpherix PROOX incubator.
Hypoxia settings were: (i) 10% O2,5%C O 2 and 85%
N2;(ii)5%O2,5%CO 2 and90%N2;and(iii)2.5%O2,
5%CO2 and 92.5% N2. A lower oxygen concentration
(1%) was attempted, but cardiomyocytes had difﬁculty
surviving under these conditions. The duration of
hypoxiawas1 h,2 h,4 h,6 horlonger.Thecontentofthe
culture was left unchanged during the experiment.
Antibodies and reagents
A rabbit polyclonal antibody against myocardin, mouse
mAbs (monoclonal antibodies) against JNK (c-Jun N-
terminalkinase)andananti-actinantibodywereobtained
from Santa Cruz Biotechnology. Mouse mAbs against
p38 MAPK (mitogen-activated protein kinase), ERK
(extracellular-signal-regulated kinase), phospho-ERK
and PI3K (phosphoinositide 3-kinase) were purchased
from BD Bioscience Pharmingen. PD98059, SB203580,
SP600125 and wortmannin were purchased from
Calbiochem. All other chemicals of reagent grade were
obtainedfromSigma.TherolesofJNK,p38MAPK,ERK
and PI3K in hypoxia-induced myocardin expression
were determined by pre-treatment of the myocytes with
25 μmol/l SP600125 (a potent cell-permeant selective
and reversible inhibitor of JNK), 3 μmol/l SB203580 (a
highly speciﬁc cell-permeant inhibitor of p38 MAPK),
50 μmol/l PD98059 (a speciﬁc and potent inhibitor of
the ERK pathway) or 50 nM wortmannin (a speciﬁc and
potent inhibitor of PI3K) for 30 min before hypoxia.
AngII and the anti-AngII antibodies were from Bachem.
To examine the effect of ARBs, cardiomyocytes were
treated with 100 nmol/l losartan (Merck).
RNA isolation and real-time quantitative
PCR
Total cellular RNA was extracted from cardiomyocytes
(approx. 1.5×106 cells) using TRI reagent (Molecular
Research Center, Cincinnati, OH, U.S.A.), according
to the manufacturer’s instructions. A total of 1 μgo f
total RNA was reverse-transcribed by M-MuLV reverse
transcriptase (Finnzyme) in a total volume of 20 μl.
The reverse transcriptase products were ampliﬁed with
DyNAmo HS SYBR Green qPCR Kit (Finnzyme) in the
reaction mix containing DyNAmo SYBR Green master
mix and primers. Primers were designed for detection of
myocardin gene expression (forward: 5 -GGACTGCT-
CTGGCAACCCAGTGC-3 ; reverse: 5 -CATCTGCT-
GACTCCGGGTCATTTGC-3 ). GAPDH (glyceral-
dehyde-3-phosphate dehydrogenase) gene expression
wasusedasinternalcontrols(forward:5 -GAGAGGCT-
CTCTGTCGACTAC-3 ;r e v e r s e :5  -TAGTGTAGG-
TTGGGCGCTCAA-3 ) and did not change under the
above conditions.
Western blot analysis
Cardiomyocytes were washed in PBS and lysed with
RIPA buffer containing 1% (v/v) Nonidet P40, 0.5%
SDS and protease inhibitor cocktail containing 10 μg/ml
PMSF, 2 μg/ml leupeptin, 2 μg/ml pepstatin A and
2 μg/ml aprotinin. Cells were disrupted by intermittent
sonication.Aftercentrifugation,theamountofproteinin
the supernatant was measured using BSA as a standard.
Cell lysates were then subjected to SDS/PAGE followed
by Western blotting. Antigen–antibody complexes were
detected by HRP (horseradish peroxidase)-labelled
rabbit anti-(mouse IgG) or goat anti-(rabbit IgG) with
an ECL (enhanced chemiluminescence) detection system
(Pierce).
RNA interference
Neonatalcardiomyocytesweretransfectedwith800 ngof
ERK- and myocardin-annealed siRNA (small interfering
RNA; Dharmacon). ERK siRNAs are target-speciﬁc
20–25-nt siRNAs designed to knock down gene
expression. siRNA sequences were 5 -GACCGGAU-
GUUAACCUUUAUU-3  (sense) and 5 -PUAAAG-
GUUAACAUCCGGUCUU-3  (antisense) for ERK.
Myocardin siRNA sequences were 5 -UGCAACUG-
CAGAAGCAGAAUU-3  (sense) and 5 -UGCAA-
CUGGUCUUGCAGAAUU-3  (scramble). As a neg-
ative control, a non-targeting (control) siRNA (Dharma-
con) was used. For transfection of neonatal cardiomyo-
cytes with siRNA oligonucleotides, Effectene transfec-
tion reagent was used according to the manufacturer’s in-
structions (Qiagen). After incubation at 37◦C, cells were
kept under hypoxia and analysed by Western blotting.
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EMSA (electophoretic mobility-shift assay)
Nuclear protein concentrations from cultured myo-
cytes were determined using the Bradford method
(Bio-Rad Laboratories). Consensus and control
oligonucleotides (Research Biolabs) were labelled by
polynucleotide kinase incorporation of [γ-32P]ATP. The
consensus oligonucleotide sequence of myocardin was
5 -GGACTGCTCTGGCAACCCAGTGC-3  and the
reverseprimerwas5 -CATCTGCTGACTCCGGGTC-
ATTTGC-3 . The myocardin mutant oligonucleotide se-
quencewas5 -GGACTGCTCTTTCAACCCAGTGC-
3 . EMSA was performed as described previously [24].
In each case, mutant or unlabelled oligonucleotide was
used as a control to compete with labelled sequences.
ELISA for AngII
AngII was measured in cell lysates and the culture
medium by a quantitative competitive ELISA, using
a speciﬁc anti-AngII antibody (Peninsula Labs), as
described previously [29].
Promoter activity assay
A−968to+44 bpratmyocardinpromoterconstructwas
generated as follows. Rat genomic DNA was ampliﬁed
with forward (5 -GGACTGCTCTGGCAACCCA-
GTGC-3 ) and reverse (5 -CATCTGCTGACTCCG-
GGTCATTTGC-3 ) primers. The ampliﬁed product
was digested with MluI and BglII restriction enzymes
and ligated into the pGL3-basic luciferase plasmid
vector (Promega) digested with the same enzymes. The
myocardin promoter contains myocardin-conserved
sites (GGGACTT) at −285 to −279 bp. For the mutant,
the myocardin-binding sites were mutated using a
mutagenesis kit (Stratagene). Site-speciﬁc mutations
were conﬁrmed by DNA sequencing. Plasmids were
transfected into cardiomyocytes using a low-pressure
accelerated gene gun (Bioware).
Determination of protein synthesis
Protein synthesis was examined by measuring
[3H]proline incorporation into the cells. Cultured
cardiomyocytes were divided into the following groups:
(i) control group, in which the cells were cultured in
serum-free DMEM/F12; and (ii) hypoxia group, in
which cells were cultured in 2.5% O2 in serum-free
DMEM/F12. Each experiment was repeated six times.
Cardiomyocytes were ﬁrst grown in DMEM/F12 with
10% (v/v) FBS (fetal bovine serum) and 200 mg/l
l-glutamine, and then seeded in 24-well plates at 1×105
cells/well in DMEM/F12+10% (v/v) FBS. After
synchronization of cardiomyocytes, the medium was
changed to serum-free DMEM/F12. Cardiomyocytes
were incubated under hypoxia and exposed to
[3H]proline (1 μCi/well) for the last 8 h of the 24 h
incubation period. After incubation, cells were washed
with ice-cold PBS and 10% (v/v) TCA (trichloroacetic
acid)-insoluble [3H]proline was collected on glass ﬁbre
ﬁlters (Whatman) and the radioactivity was determined
using a liquid-scintillation counter (LS 6500; Beckman).
Statistical analysis
All results were expressed as means+ −S.D. Statistical
signiﬁcance was evaluated using ANOVA, followed by
a Tukey–Kramer multiple comparisons test (GraphPad
Software). A value of P<0.05 was considered as
statistically signiﬁcant.
RESULTS
Hypoxia increases the expression of
myocardin in cultured cardiomyocytes
We used different degrees of hypoxia (10%, 5%
and 2.5% O2) for various times (1, 2, 4 and 6 h).
Myocardin expression was most evident in cells cultured
in 2.5% O2 for 4 h compared with the other conditions
(Supplementary Figure S1 at http://www.clinsci.org/
cs/119/cs1190273add.htm) and, therefore, we used this
concentration for further analysis. There was no signi-
ﬁcant difference in pH between the different degrees of
hypoxia. In 2.5% O2, myocardin mRNA was maximally
expressed after 1 h and decreased gradually thereafter
(Figure 1C). Myocardin protein levels also increased
gradually and reached a peak after 4 h (Figures 1A and
1B). Protein levels were suppressed using myocardin
siRNA (Supplementary Figure S2 at http://www.clinsci.
org/cs/119/cs1190273add.htm).
Hypoxia increases the expression of
myocardin in cultured cardiomyocytes
through the ERK pathway
Previous studies have indicated that hypoxia may
stimulate gene expression through different pathways,
including ERK, JNK, p38 MAPK and PI3K/Akt [30],
and therefore hypoxia may increase the expression of
myocardin through one of these pathways. Different
signalling pathway inhibitors were used to investigate
whichpathwaywasinvolved(PD98059,anERKpathway
inhibitor, SP600125, a JNK inhibitor, SB203580, a p38
MAPK inhibitor, and wortmannin, a PI3K inhibitor). Of
the inhibitors used, myocardin expression was blocked
most effectively by PD98059, and similar effects were
also achieved using ERK siRNA (Figures 2A and 2B).
Hypoxia increases ERK phosphorylation in
cultured neonatal cardiomyocytes
ERK phosphorylation was also increased to a maximal
level 1 h after 2.5% O2 and then declined gradually
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Figure 1 Effect of hypoxia on myocardin protein and mRNA
levels
Neonatal cardiomyocytes were subjected to hypoxia for 1–6 h, and total cell
lysates were immunoblotted with an anti-myocardin antibody (A) or (C) extracted
to determine mRNA levels. (A and B) Myocardin protein level increased and
reached a peak after 4 h of hypoxia. Actin is used to show equal amounts of
protein loading in each lane. (C) Myocardin mRNA levels reached a peak after
1 h of hypoxia and then declined. ∗P <0.01 compared with normoxia control
(n=3).
thereafter (Figures 2C and 2D). PD98059 and ERK
siRNA were effective in blocking ERK phosphorylation
induced by 2.5% O2 (Figures 2C and 2D). In addition,
ERK phosphorylation was also suppressed by losartan
(Figures 2C and 2D).
AngII induced by hypoxia increases
myocardin levels in cultured
cardiomyocytes
Under 2.5% O2, AngII protein levels increased and
reachedapeak1 hlater(earlierthanthemaximumexpres-
sion of myocardin after 4 h) before declining gradually
thereafter (Figure 3A). Exogenous addition of AngII
(10nmol/l) increased myocardin protein expression
similarto2.5%O2 (Figure3C).Myocardinproteinlevels
increased after hypoxia, but were suppressed by losartan
(100nmol/l)andtheanti-AngIIantibody(Figures3Band
3C). Hypoxia-induced AngII expression was partially
suppressed by PD98059 and ERK siRNA (Figure 3D).
Hypoxia increases the binding of
myocardin and SRF, and enhances the
gene transcription activity of myocardin
Under 2.5% O2, increased binding activity between
myocardin and SRF was detected by EMSA, and
PD98059 and losartan decreased this binding activity
(Figure 4A). This ﬁnding indicated that hypoxia in
cardiomyocytes may increase the co-operative binding
between myocardin and SRF. Furthermore, hypoxia-
induced AngII expression and ERK phosphorylation
may increase myocardin expression and myocardin/SRF
binding activity.
We also used a luciferase reporter assay to identify the
gene transcription activity of myocardin in cardiomyo-
cytes under hypoxia (Figure 4B). We found that hypoxia
increasedtranscriptionalactivityofmyocardin,whereasa
myocardinmutantfailedtohavethesameeffect.Exogen-
ous addition of AngII also increased the transcriptional
activity of myocardin. PD98508 and losartan suppressed
the transcriptional activity of myocardin.
Hypoxia in cardiomyocytes increases
myocardin expression in the nucleus,
hypertrophic marker and phenotype
modulation, and gene transcription to
induce cardiomyocyte hypertrophy
In cardiomyocytes under hypoxia, we have shown
increased myocardin expression and enhanced
transcriptionalactivityincardiomyocytes.Next,weused
confocal microscopy to identify the effect of myocardin
on cardiomyocytes (Supplementary Figure S3 at http://
www.clinsci.org/cs/119/cs1190273add.htm). Confocal
microscopy showed increased myocardin expression in
thenucleusfrom2to4 hafterhypoxia,whichcontributed
to a hypertrophic change in the cardiomyocytes
(Supplementary Figures 3B and 3C). AngII increased
further the expression of myocardin in the nucleus
of cardiomyocytes (Supplementary Figure 3F), and
myocardin expression was suppressed by PD98059
(Supplementary Figure 3D) and losartan (Supplementary
Figure 3E). The effect on BNP, a hypertrophic
cardiomyocyte marker, was also determined after
hypoxia treatment. Results showed that BNP protein
levels increased after hypoxia and reached a peak
after 4 h (Figures 5A and 5B). MHC, a major cardio-
myocyte phenotype marker, also increased signiﬁcantly
after hypoxia-induced cardiomyocyte hypertrophy
(Figure 5C and 5D). We also evaluated protein
synthesis in cardiomyocytes by measuring [3H]proline
incorporation into the cells. Results showed an increase
in protein synthesis after hypoxia for 4 to 8 h, which
representedahypertrophicchangeinthecardiomyocytes
(Figure 6). Pre-treatment with PD98059, losartan and
myocardin siRNA inhibited the hypoxia-induced
protein synthesis. The exogenous addition of AngII
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Figure 2 Effect of signalling pathway inhibitors on hypoxia-induced myocardin expression and ERK phosphorylation
(A and B) ERK pathway mediates hypoxia-induced myocardin expression in neonatal cardiomyocytes. Neonatal cardiomyocytes were pre-treated with an ERK pathway
inhibitor (PD98059), a JNK inhibitor (SP600125), a p38 MAPK inhibitor (SB203580), a PI3K/Akt inhibitor (wortmannin) or ERK siRNA, followed by hypoxia for 4 h.
Neonatal cardiomyocytes were harvested and cell lysates were analysed by Western blotting using an anti-myocardin antibody. Result are normalized to actin levels.
∗P <0.01 compared with normoxia control; #P <0.01 compared with hypoxia for 4 h (n=3). (C and D) Hypoxia-induced phosphorylation of ERK in neonatal
cardiomyocytes. Neonatal cardiomyocytes were subjected to normoxia or hypoxia for 1–6 h in the presence or absence of inhibitors, and cell lysates were collected for
Western blot analysis using antibodies against total ERK (T-ERK) and phospho-ERK (P-ERK). ∗P <0.01 compared with normoxia control; #P <0.01 compared with
hypoxia for 1 h (n=3).
and conditioned medium also increased [3H]proline
incorporation similar to the effect of hypoxia.
DISCUSSION
Hypoxic/ischaemic injury is a commonly observed
pathological phenomenon in cardiovascular diseases, in-
cludingcoronaryarterydisease,carotidstenosis,myocar-
dial infarction and heart failure. In cardiomyocytes,
hypoxic/ischaemic injury forms a stress phenomenon
resulting in the expression of fetal cardiac-restricted
genes [1–4]. Cardiomyocyte hypertrophy is the ﬁrst
adaptive phenomenon, with enlargement of cells and
organelles,andmayﬁnallyresultinheartfailureordilated
cardiomyopathy, which remains a major contributor
to cardiovascular mortality and morbidity [4,5]. In
the present study, the following novel ﬁndings are
reported: (i) the effect of hypoxia on myocardin to cause
cardiomyocyte hypertrophy; (ii) the effect of hypoxia
on the expression of AngII, and the effect of AngII on
the induction of myocardin expression and gene
transcription in neonatal cardiomyocytes to cause
hypertrophy; and (iii) the speciﬁc signal transduction
pathwaymediatingmyocardinexpressionunderhypoxia.
The induction of AngII in cardiac myocytes to
cause cardiomyocyte hypertrophy may be controversial.
Recentstudieshaveindicatedthathypoxiaincardiomyo-
cytes results in cardiomyocyte hypertrophy and remod-
elling, and could be inhibited by ARBs [21,22]. Some
studies have also indicated that AngII expression after
different mechanical loads may induce cardiomyocyte
hypertrophy through different signal transduction
pathways [25,26]. However, Zou et al. [31] have shown
that mechanical stress activates the AT1R without the
involvement of AngII and via an AngII-independent
mechanism in cardiomyocytes. Without the involvement
of AngII, mechanical stress not only activates ERK and
increases phosphoinositide production in vitro, but also
induces cardiac hypertrophy in vivo. Mechanical stretch
also induces the association of the AT1R with JAK2
(Janus kinase 2) and the translocation of G-proteins into
the cytosol.
The effect of hypoxia on the expression of AngII
and the induction of cardiomyocyte hypertrophy by
AngII after hypoxia have not been studied before. In the
present study, AngII protein levels increased and reached
a peak 1 h after hypoxia, which indicated that hypoxic
injury also stimulated AngII expression. Our present
study also indicated that both hypoxia-induced AngII
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Figure 3 Hypoxia induces AngII expression and mediates
hypoxia-induced myocardin expression
(A) AngII was measured in cell lysates and the culture medium by a quantitative
competitive ELISA, using a speciﬁc anti-AngII antibody, following 1–6 h of hypoxia.
(B and C) Neonatal cardiomyocytes were subjected to normoxia or hypoxia for
4 h in the absence or presence of losartan (100 nmol/l) or an anti-AngII
antibody and the addition of exogenous AngII (10 nmol/l). Total cell lysates were
immunoblotted with an anti-myocardin antibody. Actin is used to show equal
amounts of protein loading in each lane. (D) Hypoxia-induced AngII expression
was suppressed by PD98059 and ERK siRNA. ∗P <0.01 compared with normoxia
control; #P <0.01 compared with 4 h of hypoxia; $P <0.05 compared with
1 h of hypoxia (n=3).
Figure 4 Hypoxia induces myocardin/SFR binding (A)
and myocardin transcriptional activity (B and C) in
cardiomyocytes
(A) Increased binding between myocardin and SRF under 2.5% O2 as determined
using an EMSA. The binding between myocardin and SRF was suppressed by
PD98059 and losartan. (B) Wild-type and myocardin mutant used for the luciferase
assay. (C) Hypoxia (2.5% O2) increased the transcriptional activity of myocardin
when compared with the myocardin mutant (Mut) as determined using a luciferase
reporter assay. The transcriptional activity was suppressed by PD98059 and
losartan. Addition of exogenous AngII (10 nmol/l) increased the transcriptional
activity in neonatal cardiomyocyte similar to that of 2.5% O2. ∗P <0.01
compared with normoxia control; #P <0.01 compared with 6 h (n=3).
expression and exogenous addition of AngII (without
hypoxia) increased transcriptional activity in neonatal
cardiomyocytes to cause cardiomyocyte hypertrophy.
Our present results suggest that: (i) hypoxic injury to
cardiomyocytes also stimulates the expression of AngII,
similar to other mechanical loads; and (ii) hypoxic-
induced AngII expression plays a role in cardiomyocyte
hypertrophy through increased gene transcription.
Furthermore, previous studies have not identiﬁed the
relationship between AngII and myocardin and their
regulation by gene transcription in cardiomyocytes.
Earlier studies indicated that AngII-induced smooth
muscle α-actin gene transcription would result in VSMC
hypertrophy [23]. That study indicated further that
myocardin stimulation and VSMC gene transcription
was enhanced by AngII through AT1Rs [23]. CArG
boxes in VSMCs are necessary for AngII-induced
gene transcription. Both dominant-negative myocardin
andmyocardinsiRNAdecreasedAngII-mediatedVSMC
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Figure 5 Hypoxia induces the expression of BNP and MHC
in cardiomyocytes
BNP (A and B) and MHC (C and D) protein levels were both increased after
hypoxia (2.5% O2), reaching peak levels after 4 h.∗P <0.01 compared with
normoxia control (n=3).
gene transcription. Therefore the co-operative effect of
AngII and myocardin increased gene transcription in
VSMCs to induce VSMC hypertrophy [23]. However,
no other previous studies have discussed the relationship
between AngII and myocardin under hypoxia to
cause cardiomyocyte hypertrophy. Our present study
indicated that hypoxia-induced AngII expression
stimulated both myocardin expression and myocardin-
related gene transcription in neonatal cardiomyocytes. In
addition, our present study has also identiﬁed the signal
transductional pathway responsible for mediating the
expression of myocardin under hypoxia. By using signal
transduction pathway inhibitors, the ERK pathway
was shown to be responsible for the induction of myo-
cardin. Similarly, ERK phosphorylation enhanced the
expression of myocardin, and ERK siRNA repressed
the expression of myocardin. Thus we can conclude
that the ERK pathway mediates the induction of myo-
cardin expression after hypoxia.
In regard to the relationship between AngII and ERK,
previousstudies[26,32]andourpresentstudyhaveindic-
ated that AngII expression may be induced via the ERK
pathway to cause cardiomyocyte hypertrophy. Thus the
ARB could effectively suppress ERK phosphorylation
by blocking the expression of AngII to prevent cardiac
hypertrophy (Figures 2C and 2D). Hypoxia-induced
AngIIexpressionwasanovelﬁndinginthepresentstudy.
We found that the ERK pathway inhibitor PD98059
and/or ERK siRNA could inhibit the expression of
AngII, but the effect was partial (Figure 3D). This
ﬁnding suggests that hypoxia-induced AngII expression
may possibly be activated by several different pathways
and that the ERK pathway is one of these signalling
pathways.
With regards to myocardin-related cardiomyocyte
hypertrophy, previous studies have also investigated this
[14–17,33]. Some pro-hypertrophic agonists, such as
AngII or ET-1 (endothelin-1), can result in cardiomyo-
cyte hypertrophy by increasing transcriptional activities
Figure 6 Hypoxia induces protein synthesis in neonatal cardiomyocytes
Incorporation of [3H]proline into neonatal cardiomyocytes increased after hypoxia and the exogenous addition of AngII for 4–8 h, and was suppressed by PD98059,
losartan, and myocardin siRNA. ∗P <0.01 compared with normoxia control; #P <0.01 compared with hypoxia (n=6). CM, conditioned medium.
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in cardiomyocytes. Multiple signal transductional cas-
cadesmaybeinvolvedinthesehypertrophicmechanisms.
Accordingtoourpresentresults,weidentiﬁedERKtobe
involved in the signal transduction pathway facilitating
AngII-stimulated myocardin-related gene transcription
during hypoxia. Myocardin-related gene transcription
in cardiomyocytes is through myocardin/SRF binding
to the CArG boxes of target genes. We also found that
AngII- and ERK-mediated cardiomyocyte hypertrophy
after hypoxia could be induced by myocardin as not only
theERKpathwayinhibitorandARB,butalsomyocardin
siRNA inhibited protein synthesis (representing
cardiomyocytehypertrophy)inneonatalcardiomyocytes
under hypoxia. Another signal pathway not related to
myocardin which causes cardiomyocyte hypertrophy
involves the binding of the transcriptional factor
GATA4 to GATA4 sites of target genes [20]. A previous
study has identiﬁed GSK (glycogen synthase kinase)
3β, a ubiquitously expressed serine/threonine kinase,
as having a role in inhibiting myocardin expression
through the PI3K/Akt pathway [20]. Furthermore,
that study, performed in cultured cardiomyocytes and
transgenic mice, has shown that GSK3β inactivation
by phosphorylation is necessary and sufﬁcient for the
development of cardiomyocyte hypertrophy [20]. Our
present study found that an ARB is another potent
agent capable of inhibiting gene transcription and
cardiomyocyte hypertrophy by suppressing AngII and
myocardin simultaneously through the ERK pathway.
Therefore commercially available ARBs may be suitable
for treating patients with myocardial hypertrophy,
hypertrophic cardiomyopathy and hypertension to
prevent further cardiomyocyte hypertrophy and heart
failure.
In conclusion, hypoxia in cultured rat neonatal
cardiomyocytes induces the expression of AngII.
AngII and the ERK pathway mediate the induction of
myocardin expression, with subsequent cardiomyocyte
hypertrophy through increased transcriptional activities.
Cardiomyocyte hypertrophy after hypoxia could be
identiﬁed by the expression of the hypertrophic mar-
ker (BNP) and the cardiomyocyte phenotype marker
(MHC), increased protein synthesis, and hypertrophic
changes in cardiomyocytes. Hypoxia-induced AngII ex-
pression has a similar effect to the exogenous addition of
AngIIandmayincreaseboththeexpressionofmyocardin
and transcriptional activity in cardiomyocytes. Cardio-
myocyte hypertrophy can be prevented using an ARB,
which inhibits the effect of AngII and myocardin.
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Angiotensin II and the ERK pathway mediate
the induction of myocardin by hypoxia in
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Figure S1 Hypoxia increases the expression of myocardin
protein in cultured rat neonatal cardiomyocytes
Neonatal cardiomyocytes were subjected to normoxia or different degrees of
hypoxia for 4 h, and total cell lysates were immunoblotted with the anti-myocardin
antibody. Actin is used to show equal amounts of protein loading in each lane.
#P < 0.05 and ∗P < 0.01 compared with normoxia control (n = 3).
Figure S2 Effect of myocardin siRNA on myocardin
expression in cardiomyocytes under 2.5% O2
Myocardin protein levels increased and reached a peak after hypoxia for 4 h,
which was suppressed by myocardin siRNA. Actin is used to show for equal
amounts of protein loading in each lane. ∗P < 0.01 compared with normoxia
control; #P < 0.01 compared with 4 h (n = 3).
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Figure S3 Confocal microscopy identiﬁes the expression of
myocardin in the nucleus of neonatal cardiomyocytes after
hypoxia
(A) Cardiomyocytes under normoxia. (B and C) Myocardin protein (green) levels
increased in the nucleus (blue) of neonatal cardiomyocytes from 2 to 4 h. (D and
E) ERK pathway inhibitor (PD98059) and ARB (losartan) suppressed the expression
of myocardin. (F) AngII increased the expression of myocardin in the nuclei of
neonatal cardiomyocytes.
Received 4 February 2010/5 May 2010; accepted 6 May 2010
Published as Immediate Publication 6 May 2010, doi:10.1042/CS20100084
C   The Authors Journal compilation C   2010 Biochemical Society
© 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.